SCHEMBL24723852

SCHEMBL24723852

CC(O)c1ccc(S(=O)(=O)N(C)C(=O)OC(C)(C)C)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1I2 O75469 1/20 0.40
MMP13 P45452 1/20 0.36
HSD11B1 P28845 1/20 0.36
ALDH1A1 P00352 3/20 0.35
CA1 P00915 2/20 0.35
CA2 P00918 2/20 0.35
CA9 Q16790 2/20 0.35
CA4 P22748 1/20 0.35
CA7 P43166 1/20 0.35
BMP1 P13497 1/20 0.35
CCR5 P51681 1/20 0.35
CA12 O43570 1/20 0.35
CA14 Q9ULX7 1/20 0.35
KEAP1 Q14145 2/20 0.34
NFE2L2 Q16236 1/20 0.34
HPGD P15428 1/20 0.34
GAA P10253 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
MAOA P21397 1/20 0.34
MAOB P27338 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31036586 0.87 MMP13 (0.35) MMP13HSD11B1ALDH1A1CA1CA2
SCHEMBL1864283 0.82 ALDH1A1 (0.51) ALDH1A1CA9CA12KEAP1NFE2L2
SCHEMBL22517147 0.81 CA12 (0.40) HSD11B1ALDH1A1CA1CA2CA9
SCHEMBL9986889 0.81 KMT2A (0.46) MMP13HSD11B1ALDH1A1HPGDGAA
SCHEMBL1858049 0.81 ALDH1A1 (0.39) MMP13HSD11B1ALDH1A1CA1CA2
SCHEMBL28034923 0.80 HSD11B1 (0.56) MMP13HSD11B1ALDH1A1CCR5SMN1; SMN2
SCHEMBL24723850 0.79 CA12 (0.42) NR1I2HSD11B1ALDH1A1CA1CA2
SCHEMBL1858895 0.77 HSD11B1 (0.39) MMP13HSD11B1ALDH1A1CA1CA2
SCHEMBL22517138 0.75 LMNA (0.57) MMP13ALDH1A1HPGDGAAMAOA
SCHEMBL23536576 0.74 ALDH1A1 (0.52) NR1I2ALDH1A1CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240287070-A1 FUSED HETEROCYCLIC DERIVATIVES JOHNSON & JOHNSON (CHINA) INVESTMENT LTD. (CN) 2024-08-29 US disclosed
WO-2022253259-A1 FUSED HETEROCYCLIC DERIVATIVES Janssen Sciences Ireland Unlimited Company (IE) 2022-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240287070-A1 FUSED HETEROCYCLIC DERIVATIVES HAVCR2, HCCS, GOT2 NR1I2 120/4885MMP13 3297/4885HSD11B1 328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.